Lan Tian, Zhang Jingjing, Lu Yi
GlucoSentient, Inc., 60 Hazelwood Drive, Champaign, IL 61820, USA.
Department of Chemistry, University of Illinois at Urbana-Champaign, 601 S. Mathews Ave., Urbana, IL 61801, USA.
Biotechnol Adv. 2016 May-Jun;34(3):331-41. doi: 10.1016/j.biotechadv.2016.03.002. Epub 2016 Mar 3.
Recent advances in mobile network and smartphones have provided an enormous opportunity for transforming in vitro diagnostics (IVD) from central labs to home or other points of care (POC). A major challenge to achieving the goal is a long time and high costs associated with developing POC IVD devices in mobile Health (mHealth). Instead of developing a new POC device for every new IVD target, we and others are taking advantage of decades of research, development, engineering and continuous improvement of the blood glucose meter (BGM), including those already integrated with smartphones, and transforming the BGM into a general healthcare meter for POC IVDs of a wide range of biomarkers, therapeutic drugs and other analytical targets. In this review, we summarize methods to transduce and amplify selective binding of targets by antibodies, DNA/RNA aptamers, DNAzyme/ribozymes and protein enzymes into signals such as glucose or NADH that can be measured by commercially available BGM, making it possible to adapt many clinical assays performed in central labs, such as immunoassays, aptamer/DNAzyme assays, molecular diagnostic assays, and enzymatic activity assays onto BGM platform for quantification of non-glucose targets for a wide variety of IVDs in mHealth.
移动网络和智能手机的最新进展为将体外诊断（IVD）从中心实验室转变为家庭或其他护理点（POC）提供了巨大机遇。实现这一目标的主要挑战是在移动健康（mHealth）领域开发POC IVD设备所需的时间长且成本高。我们和其他研究人员并非针对每个新的IVD目标开发新的POC设备，而是利用血糖仪（BGM）数十年的研究、开发、工程和持续改进成果，包括那些已与智能手机集成的血糖仪，并将其转变为一种通用的医疗保健仪器，用于对多种生物标志物、治疗药物和其他分析目标进行POC IVD检测。在本综述中，我们总结了将抗体、DNA/RNA适配体、DNA酶/核酶和蛋白酶对靶标的选择性结合转导并放大为可通过市售BGM测量的葡萄糖或NADH等信号的方法，从而能够将许多在中心实验室进行的临床检测，如免疫测定、适配体/DNA酶测定、分子诊断测定和酶活性测定，应用于BGM平台，以对mHealth中各种IVD的非葡萄糖靶标进行定量。
